ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026
Prevalence of high-risk plasma p-tau217 levels and 5-year transition of risk status in 70-year-olds.
Anna Dittrich, Burak Arslan, Tobias Skillbäck, Lina Rydén, Hlin Kvartsberg, Johan Gobom, Kaj Blennow, Henrik Zetterberg, Silke Kern, Ingmar Skoog
Abstract read
In one paragraphArticle in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Burak ArslanDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Tobias SkillbäckNeuropsychiatric Epidemiology Unit, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.
Lina RydénNeuropsychiatric Epidemiology Unit, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.
Hlin KvartsbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Johan GobomDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Silke KernNeuropsychiatric Epidemiology Unit, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.
Ingmar SkoogNeuropsychiatric Epidemiology Unit, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.
Funding
Alzheimer Drug Discovery Foundation (ADDF) #201809-2016862Alzheimerfonden AF-554461AF-647651AF-743701AF-844671AF-930868AF-940139AF-968441AF-980935Alzheimerfonden AF-842471,AF-737641,AF-929959,AF-939825,FO2024-0341-HK-76Alzheimer's Association (#ADSF-21-831376-C,#ADSF-21-831381-C,#ADSF-21-831377-C,and#ADSF-24-1284328-CAlzheimer's Drug Discovery Foundation #201809-2016862anonymous donorCure Alzheimer's FundEivind och Elsa K:son Sylvans stiftelseEU Joint Programme - Neurodegenerative Disease Research JPND2021-00694European Partnership on MetrologyEuropean Union's Horizon 2020 research and innovation programme 860197European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grantEuropean Union's Horizon Europe research and innovation programme 101053962European Union's Horizon Europe Research and Innovation ProgrammeFamiljen Beiglers StiftelseFamiljen Erling-Perssons StiftelseFamiljen Rönströms StiftelseForskningsrådet om Hälsa, Arbetsliv och Välfärd 2013-2496Forskningsrådet om Hälsa, Arbetsliv och Välfärd 2018-00471Forskningsrådet om Hälsa, Arbetsliv och Välfärd AGECAP2013-2300Hjärnfonden #FO2022-0270Hospitals Biomedical Research CentreKonung Gustaf V:s och Drottning Victorias FrimurarestiftelseNational Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, the UK Dementia Research Institute at UCLNEuroBioStand #22HLT07Olav Thon StiftelsenStiftelsen för Gamla TjänarinnorStiftelsen Psykiatriska ForskningsfondenSwedish Research Council for HealthSwedish State Support for Clinical ResearchSwedish state under the agreement between the Swedish government and the county councilsthe AD Strategic Fundthe ALF-agreement ALFGBG-1005471 ALFGBG-965923 ALFGBG-81392 ALF GBG-771071the Bluefield Projectthe Erling-Persson Family Foundationthe National Institute for Health and Care Research University College LondonThe Swedish Brain Foundation FO2024-0097,FO2014-0207FO2016-0214FO2018-0214FO2019-0163FO2020-0235the Swedish Research Council 2012-5041,2015-02830,2013-8717,2017-00639,2019-01096,2022-00882the Swedish Research Council 2023-00356,2022-01018,2019-02397,2019-02075,2019-02075_15the Swedish state under the agreement between the Swedish government and the county councils, the ALF agreement ALF965812 ALF 716681the Swedish state under the agreement between the Swedish government and the county councils, the ALF agreement ALFGBG-71320the Swedish state under the agreement between the Swedish government and the county councils, the ALF agreement ALFGBG-984092the UK Dementia Research Institute at UCL UKDRI-1003Working Life and Wellfare 2013-1202 2018-00471Working Life and Wellfare 2013-2300 2013-2496 2018-00471
6 · The paper itselfAbstract
introductionHigh-risk plasma p-tau217 levels predict amyloid-β pathology in Alzheimer's disease, but little is known about the prevalence and temporal dynamics in the general population.
methodsParticipants from the Gothenburg H70 Birth Cohort Study in Sweden were examined (n = 1157) and re-examined after 5-7 years (n = 771). Prevalence and 5-7 year transition of high-risk plasma p-tau217 status was determined among community-dwelling 70-year-olds.
resultsHigh-risk plasma p-tau217 prevalence was 3.6% at age 70 and 7.0% at age 75-77 years. Eighty-nine percent remained low-risk and 4% converted to high-risk at follow-up. Prevalence of dementia at follow-up was 1.7% if remaining in the low-risk group and 21.4% if transitioning to the high-risk group. Prevalence of dementia among participants staying in the high-risk group was 16.7% at follow-up. DISCUSSION: Individuals with low-risk plasma p-tau217 were unlikely to transition over 5-7 years. However, transitioning to a higher risk-category was associated with a higher prevalence of cognitive disability.
Indexed as
Dementiatau ProteinsAgedBiomarkersDisease ProgressionFemaleHumansLongitudinal StudiesMalePrevalenceRisk FactorsSwedenBiomarkersMAPT protein, humantau ProteinsAlzheimer's diseasebiomarkerscohort studycommunity‐baseddementialongitudinalplasma p‐tau217
Identifiers
PMID42252493
PMCPMC13243198
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390